KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Deferred Taxes (2016 - 2025)

Edwards Lifesciences has reported Deferred Taxes over the past 17 years, most recently at $54.4 million for Q4 2025.

  • Quarterly results put Deferred Taxes at $54.4 million for Q4 2025, down 44.77% from a year ago — trailing twelve months through Dec 2025 was $117.6 million (down 63.64% YoY), and the annual figure for FY2025 was $117.6 million, down 63.64%.
  • Deferred Taxes for Q4 2025 was $54.4 million at Edwards Lifesciences, up from $18.0 million in the prior quarter.
  • Over the last five years, Deferred Taxes for EW hit a ceiling of $123.0 million in Q3 2024 and a floor of -$10.8 million in Q1 2021.
  • Median Deferred Taxes over the past 5 years was $49.0 million (2022), compared with a mean of $50.4 million.
  • Biggest five-year swings in Deferred Taxes: tumbled 200.0% in 2021 and later surged 1287.18% in 2022.
  • Edwards Lifesciences' Deferred Taxes stood at $61.5 million in 2021, then skyrocketed by 72.03% to $105.8 million in 2022, then dropped by 13.61% to $91.4 million in 2023, then grew by 7.77% to $98.5 million in 2024, then tumbled by 44.77% to $54.4 million in 2025.
  • The last three reported values for Deferred Taxes were $54.4 million (Q4 2025), $18.0 million (Q3 2025), and $20.9 million (Q2 2025) per Business Quant data.